Bonnie W. Ramsey, MD

Bonnie W. Ramsey, MD

Cystic Fibrosis Research

Children's Title: Vice Chair for Research, Department of Pediatrics; Associate Director, Pediatric Clinical Research Center

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

"I became involved in CF research because of my mentor, Arnie Smith, who was devoted to understanding the optimal antibiotic treatments for CF lung disease. Together, we developed TOBI, an inhaled form of the antibiotic tobramycin. Soon after the drug was approved as a commercial product, I happened to be riding a hospital elevator with one of my patients and her mom. The mother turned to me and said, "I want you to know that you and the TOBI you helped develop have changed my childs and our familys lives. We no longer have to live in the hospital. My daughter is now at home and able to be a normal child. Thank you.""

  • Bonnie W. Ramsey, MD, is director of the Center for Clinical and Translational Research at Seattle Childrens Research Institute. She is the co-PI of the UW Institute for Translational Health Sciences which provides extensive clinical research infrastructure at Seattle Childrens Hospital. She is also the PI for a P30 for Cystic Fibrosis Research from the NIDDK. She is Professor and Vice Chair for research in the Department of Pediatrics and holds the Endowed Chair in Cystic Fibrosis (CF) at the University of Washington School of Medicine.

    Dr. Ramsey is member of the American Pediatric Society and the Association of American Physicians. She is an attending physician at Seattle Childrens hospital and Associate director of the CF clinic. Her career has focused on clinical care and research in the field of cystic fibrosis (CF). She is internationally recognized for her work in developing new therapies for patients with CF, and she directs the CF Therapeutics Development Network that directs clinical trials throughout the United States. She is also interested in the ethics of pediatric clinical research and has served on two Institute of Medicine committees focused on this topic. Ramsey has used her expertise in clinical and translational research to help develop infrastructure for research involving pediatric participants at the hospital.

    • Jim Camano Island, WA 01.25.11

      Watched the TV Show about Dr. Ramsey & Dr. Smith's work on C.F. I am touched by your science but more by your efforts and want to say how wonderful you both are to commit your life's work to such a worthy cause. Nicely done. Jim S....Camano Island

    Recommend Dr. Bonnie W. Ramsey
  • Award Name Award Description Awarded By Award Date
    SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017
    SEATTLE'S TOP DOCTOR - 2016 Seattle Magazine 2016
    American Thoracic Society Distinguished Achievement Award American Thoracic Society 2014
    Seattle's Top Doc Seattle Met Magazine 2013
    UW Entrepreneurial Faculty Fellow Univerisity of Washington 2012
    U.S. News Top Doctor U.S. News and World Report 2012
    Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
    Inventor of the Year University of Washington 2009

  • Manuscripts in Refereed Journals

    • Wehby G, Collett BR, Romitti P, Ansley T, Barron S, Speltz ML
      Academic achievement of children and adolescents with oral clefts
      24753523 Pediatrics, 2014 : 133(5)785-792
    • Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW
      Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
      21083385 The New England journal of medicine, 2010 Nov. : 1991-2003 PMCID:PMC3148255
    • Ashlock MA, Beall RJ, Hamblett NM, Konstan MW, Penland CM, Ramsey BW, Van Dalfsen JM, Wetmore DR, Campbell PW 3rd
      A pipeline of therapies for cystic fibrosis.
      19760548 Seminars in respiratory and critical care medicine, 2009 Oct. : 611-26
    • Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI
      Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
      17763333 The Journal of infectious diseases, 2007 Oct. : 196(7)1088-92 PMCID:PMC2723782
    • Mayer-Hamblett N, Ramsey BW, Kronmal RA
      Advancing outcome measures for the new era of drug development in cystic fibrosis.
      17652504 Proceedings of the American Thoracic Society, 2007 Aug. : 370-7 PMCID:PMC2647602
    • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
      Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
      17534969 Pediatric pulmonology, 2007 July : 42(7)610-23

    Other Publications

    • Heltshe SL, Borowitz DS, Leung DH, Ramsey B, Mayer-Hamblett N
      Early attained weight and length predict growth faltering better than velocity measures in infants with CF.
      24917114 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014 Dec. : 13(6)723-9 PMCID:PMC4252713
    • Eldredge LC, Ramsey BW
      Remarkable progress toward new treatments for cystic fibrosis.
      25466347 The Lancet. Respiratory medicine, 2014 Dec. : 2(12)962-4
    • Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Wolter DJ, Houston LS, Pope CE, Kulasekara BR, Armbruster CR, Burns JL, Retsch-Bogart G, Rosenfeld M, Gibson RL, Miller SI, Khan U, Hoffman LR
      Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.
      24863401 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014 Sept. 1 : 59(5)624-31 PMCID:PMC4148602
    • Retsch-Bogart GZ, Van Dalfsen JM, Marshall BC, George C, Pilewski JM, Nelson EC, Goss CH, Ramsey BW
      Highly effective cystic fibrosis clinical research teams: critical success factors.
      25029977 Journal of general internal medicine, 2014 Aug. : 29 Suppl 3S714-23 PMCID:PMC4124113
    • Scott CS, Nagasawa PR, Abernethy NF, Ramsey BW, Martin PJ, Hacker BM, Schwartz HD, Brock DM, Robins LS, Wolf FM, Carter-Dubois M, Disis ML
      Expanding assessments of translational research programs: supplementing metrics with value judgments.
      24064429 Evaluation & the health professions, 2014 March : 37(1)83-97 PMCID:PMC4012871
    • Rosenthal EA, Ranchalis J, Crosslin DR, Burt A, Brunzell JD, Motulsky AG, Nickerson DA, NHLBI GO Exome Sequencing Project, Wijsman EM, Jarvik GP
      Joint linkage and association analysis with exome sequence data implicates SLC25A40 in hypertriglyceridemia.
      24268658 American journal of human genetics, 2013 Dec. 5 : 93(6)1035-45 PMCID:PMC3852929
    • Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW, Scientific Advisory Group, investigators, coordinators of the Epidemiologic Study of Cystic Fibrosis
      Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
      23810128 The Journal of pediatrics, 2013 Oct. : 163(4)1152-7.e2
    • Konstan MW, Borowitz D, Mayer-Hamblett N, Milla C, Hendeles L, Murray S, Kronmal RA, Casey S, Rose LM, Morgan WJ, Ramsey BW
      Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.
      25132954 Clinical investigation, 2013 Aug. : 3(8)731-741 PMCID:PMC4131768
    • Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, Guo S, Gonzalez M, Hedges DJ, Robertson PD, Krumm N, Nickerson DA, Hershberger RE, National Heart, Lung, and Blood Institute GO Exome Sequencing Project and the Exome Sequencing Project Family Studies Project Team
      Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy.
      23418287 Circulation. Cardiovascular genetics, 2013 April : 6(2)144-53 PMCID:PMC3815606
    • Mascette AM, Bernard GR, Dimichele D, Goldner JA, Harrington R, Harris PA, Leeds HS, Pearson TA, Ramsey B, Wagner TH
      Are central institutional review boards the solution? The National Heart, Lung, and Blood Institute Working Group's report on optimizing the IRB process.
      23095928 Academic medicine : journal of the Association of American Medical Colleges, 2012 Dec. : 87(12)1710-4 PMCID:PMC4267852
    • Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d'Indy H, Braverman AC, Grandchamp B, Kwartler CS, Gouya L, Santos-Cortez RL, Abifadel M, Leal SM, Muti C, Shendure J, Gross MS, Rieder MJ, Vahanian A, Nickerson DA, Michel JB, National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project, Jondeau G, Milewicz DM
      TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome.
      22772371 Nature genetics, 2012 July 8 : 44(8)916-21 PMCID:PMC4033668
    • Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Devínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS, VX08-770-102 Study Group
      A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
      22047557 The New England journal of medicine, 2011 Nov. 3 : 365(18)1663-72 PMCID:PMC3230303
    • Ashlock MA, Beall RJ, Hamblett NM, Konstan MW, Penland CM, Ramsey BW, Van Dalfsen JM, Wetmore DR, Campbell PW 3rd
      A pipeline of therapies for cystic fibrosis.
      19760548 Seminars in respiratory and critical care medicine, 2009 Oct. : 611-26
    • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW
      Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
      19470318 Contemporary clinical trials, 2009 May : 256-68
    • Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW
      Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
      18822427 The Journal of pediatrics, 2009 Feb. : 183-8
    • Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI
      Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
      18974024 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2009 Jan. : 66-70
    • Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW
      Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
      17446337 American journal of respiratory and critical care medicine, 2007 Aug. 15 : 362-9
    • Mayer-Hamblett N, Ramsey BW, Kronmal RA
      Advancing outcome measures for the new era of drug development in cystic fibrosis.
      17652504 Proceedings of the American Thoracic Society, 2007 Aug. 1 : 370-7
    • Ramsey BW
      Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis.
      17652502 Proceedings of the American Thoracic Society, 2007 Aug. 1 : 359-63
    • Ramsey BW
      Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?
      17652503 Proceedings of the American Thoracic Society, 2007 Aug. 1 : 367-9
    • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
      Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
      17534969 Pediatric pulmonology, 2007 July : 610-23
    • Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW
      Association between pulmonary function and sputum biomarkers in cystic fibrosis.
      17234902 American journal of respiratory and critical care medicine, 2007 April 15 : 822-8
    • Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW
      Laboratory parameter profiles among patients with cystic fibrosis.
      16829217 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2007 April : 117-23
    • D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Déziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, Brittnacher M, Hayden HS, Selgrade S, Klausen M, Goodlett DR, Burns JL, Ramsey BW, Miller SI
      Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
      17493132 Molecular microbiology, 2007 April : 512-33
    • Hoffman LR, Déziel E, D'Argenio DA, Lépine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI
      Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
      17172450 Proceedings of the National Academy of Sciences of the United States of America, 2006 Dec. 26 : 19890-5
    • Hoffman LR, Déziel E, D'Argenio DA, Lépine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI
      Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
      17172450 Proceedings of the National Academy of Sciences of the United States of America, 2006 Dec. 26 : 19890-5
    • Sucharew H, Goss CH, Millard SP, Ramsey BW
      Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.
      16875884 Contemporary clinical trials, 2006 Dec. : 561-70
    • Ramsey BW
      Appropriate compensation of pediatric research participants: thoughts from an Institute of Medicine committee report.
      16829236 The Journal of pediatrics, 2006 July : S15-9
    • Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV
      Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
      16687478 Proceedings of the National Academy of Sciences of the United States of America, 2006 May 30 : 8487-92
    • Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, Aitken ML
      Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
      16610931 Human gene therapy, 2006 April : 440-7
    • Goss CH, Rubenfeld GD, Ramsey BW, Aitken ML
      Clinical trial participants compared with nonparticipants in cystic fibrosis.
      16192455 American journal of respiratory and critical care medicine, 2006 Jan. 1 : 98-104
    • Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B, Cystic Fibrosis Foundation Therapeutics Development Network
      Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
      15704203 Pediatric pulmonology, 2005 April : 39(4)339-48
    • Ernst RK, D'Argenio DA, Ichikawa JK, Bangera MG, Selgrade S, Burns JL, Hiatt P, McCoy K, Brittnacher M, Kas A, Spencer DH, Olson MV, Ramsey BW, Lory S, Miller SI
      Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis.
      14641578 Environmental microbiology, 2003 Dec. : 1341-9
    • Rosenfeld M, Ramsey BW, Gibson RL
      Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.
      14534401 Current opinion in pulmonary medicine, 2003 Nov. : 492-7
    • Gibson RL, Burns JL, Ramsey BW
      Pathophysiology and management of pulmonary infections in cystic fibrosis.
      14555458 American journal of respiratory and critical care medicine, 2003 Oct. 15 : 918-51
    • Ramsey BW
      To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa?
      12359642 American journal of respiratory and critical care medicine, 2002 Oct. 1 : 906-7
    • Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW
      Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
      12114362 Chest, 2002 July : 219-26

    Show More Hide

Overview

Clinical Interests

Cystic fibrosis

Research Focus Area

Translational Research, Cystic Fibrosis